KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells

Overview

Journal Cancer Res

Specialty Oncology

Date 2013 May 7

PMID 23644528

Citations 230

Authors

William L Berry

Ralf Janknecht

Affiliations

Soon will be listed here.

Abstract

Lysine methylation is one of the most prominent histone posttranslational modifications that regulate chromatin structure. Changes in histone lysine methylation status have been observed during cancer formation, which is thought to be a consequence of the dysregulation of histone lysine methyltransferases or the opposing demethylases. KDM4/JMJD2 proteins are demethylases that target histone H3 on lysines 9 and 36 and histone H1.4 on lysine 26. This protein family consists of three ~130-kDa proteins (KDM4A-C) and KDM4D/JMJD2D, which is half the size, lacks the double PHD and Tudor domains that are epigenome readers and present in the other KDM4 proteins, and has a different substrate specificity. Various studies have shown that KDM4A/JMJD2A, KDM4B/JMJD2B, and/or KDM4C/JMJD2C are overexpressed in breast, colorectal, lung, prostate, and other tumors and are required for efficient cancer cell growth. In part, this may be due to their ability to modulate transcription factors such as the androgen and estrogen receptor. Thus, KDM4 proteins present themselves as novel potential drug targets. Accordingly, multiple attempts are under way to develop KDM4 inhibitors, which could complement the existing arsenal of epigenetic drugs that are currently limited to DNA methyltransferases and histone deacetylases.

Citing Articles

Targeting KDM4C Prevents Heart Failure after Acute Myocardial Infarction Via Activation of SOS2.

Tan C, Chen X, Xu L, Chen J, Tu Y J Cardiovasc Transl Res. 2025; .

PMID: 39900886 DOI: 10.1007/s12265-025-10594-2.

ETV2/ER71 regulates hematovascular lineage generation and vascularization through an H3K9 demethylase, KDM4A.

Kim M, Lee R, Lee D, Song H, Ha T, Kim J iScience. 2025; 28(1):111538.

PMID: 39811655 PMC: 11732216. DOI: 10.1016/j.isci.2024.111538.

Analogue-Sensitive Inhibition of Histone Demethylases Uncovers Member-Specific Function in Ribosomal Protein Synthesis.

Kuwik J, Scott V, Chedid S, Stransky S, Hinkelman K, Kavoosi S J Am Chem Soc. 2025; 147(4):3341-3352.

PMID: 39808475 PMC: 11783601. DOI: 10.1021/jacs.4c13870.

The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications.

Duan X, Xing Z, Qiao L, Qin S, Zhao X, Gong Y Front Immunol. 2024; 15:1495221.

PMID: 39620228 PMC: 11604627. DOI: 10.3389/fimmu.2024.1495221.

Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery.

Cursaro I, Milioni L, Eslami K, Sirous H, Carullo G, Gemma S ChemMedChem. 2024; 20(4):e202400682.

PMID: 39498961 PMC: 11831885. DOI: 10.1002/cmdc.202400682.

References

Li B, Luo C, Li H, Yang P, Zhang M, Xu H . Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp Ther Med. 2012; 4(4):755-761. PMC: 3501409. DOI: 10.3892/etm.2012.662. View

Kim T, Shin S, Berry W, Oh S, Janknecht R . The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem. 2011; 113(4):1368-76. DOI: 10.1002/jcb.24009. View

Hillringhaus L, Yue W, Rose N, Ng S, Gileadi C, Loenarz C . Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J Biol Chem. 2011; 286(48):41616-41625. PMC: 3308871. DOI: 10.1074/jbc.M111.283689. View

Gray S, Iglesias A, Lizcano F, Villanueva R, Camelo S, Jingu H . Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem. 2005; 280(31):28507-18. DOI: 10.1074/jbc.M413687200. View

Kooistra S, Helin K . Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012; 13(5):297-311. DOI: 10.1038/nrm3327. View

Lee J, Smith E, Shilatifard A . The language of histone crosstalk. Cell. 2010; 142(5):682-5. PMC: 3711869. DOI: 10.1016/j.cell.2010.08.011. View

Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B . Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol. 2006; 208(4):554-63. DOI: 10.1002/path.1925. View

Li B, Zhang M, Luo C, Yang P, Li H, Xu H . Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res. 2011; 30:90. PMC: 3215938. DOI: 10.1186/1756-9966-30-90. View

Mallette F, Mattiroli F, Cui G, Young L, Hendzel M, Mer G . RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 2012; 31(8):1865-78. PMC: 3343333. DOI: 10.1038/emboj.2012.47. View

10.

Huang Y, Fang J, Bedford M, Zhang Y, Xu R . Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science. 2006; 312(5774):748-51. DOI: 10.1126/science.1125162. View

11.

Slee R, Steiner C, Herbert B, Vance G, Hickey R, Schwarz T . Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene. 2011; 31(27):3244-53. DOI: 10.1038/onc.2011.502. View

12.

Lin C, Li B, Swanson S, Zhang Y, Florens L, Washburn M . Heterochromatin protein 1a stimulates histone H3 lysine 36 demethylation by the Drosophila KDM4A demethylase. Mol Cell. 2008; 32(5):696-706. PMC: 2642969. DOI: 10.1016/j.molcel.2008.11.008. View

13.

Zhang D, Yoon H, Wong J . JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). Mol Cell Biol. 2005; 25(15):6404-14. PMC: 1190321. DOI: 10.1128/MCB.25.15.6404-6414.2005. View

14.

Liu G, Bollig-Fischer A, Kreike B, van de Vijver M, Abrams J, Ethier S . Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 2009; 28(50):4491-500. PMC: 2795798. DOI: 10.1038/onc.2009.297. View

15.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

16.

Yang J, Jubb A, Pike L, Buffa F, Turley H, Baban D . The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010; 70(16):6456-66. PMC: 4261152. DOI: 10.1158/0008-5472.CAN-10-0413. View

17.

Berdel B, Nieminen K, Soini Y, Tengstrom M, Malinen M, Kosma V . Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer. BMC Cancer. 2012; 12:516. PMC: 3547738. DOI: 10.1186/1471-2407-12-516. View

18.

Shin S, Janknecht R . Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun. 2007; 359(3):742-6. DOI: 10.1016/j.bbrc.2007.05.179. View

19.

Whetstine J, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z . Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006; 125(3):467-81. DOI: 10.1016/j.cell.2006.03.028. View

20.

Berry W, Shin S, Lightfoot S, Janknecht R . Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol. 2012; 41(5):1701-6. DOI: 10.3892/ijo.2012.1618. View